• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Atossa Therapeutics Inc.

    3/26/25 4:05:50 PM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ATOS alert in real time by email
    S-8 1 atos-20250325.htm S-8 S-8

    As filed with the Securities and Exchange Commission on March 26, 2025

    Registration No. 333-

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

    FORM S-8

    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

    ATOSSA THERAPEUTICS, INC.

    (Exact name of registrant as specified in its charter)

    Delaware
    (State or Other Jurisdiction of Incorporation or Organization)

    26-4753208

    (I.R.S. Employer Identification No.)

    Atossa Therapeutics, Inc.

    10202 5th Avenue NE, Suite 200

    Seattle, Washington 98125

    (Address of Principal Executive Offices, Zip Code)

    Atossa Therapeutics, Inc. 2020 Stock Incentive Plan, as amended


    (Full title of the plan)

    Heather Rees

    Chief Financial Officer and Secretary

    10202 5th Avenue NE, Suite 200

    Seattle, Washington 98125

    (206) 588-0256

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

    Copy to:

    Sean Feller

    Gibson, Dunn & Crutcher LLP

    2029 Century Park East, Suite 4000

    Los Angeles, CA 90067-3026

    (310) 552-8500

    ______________________________________________

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    Large accelerated filer

    ☐

    Accelerated filer

    ☐

    Non-accelerated filer

    ☑

    Smaller reporting company

    ☑

    Emerging growth company

    ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐


    INTRODUCTION

    This Registration Statement on Form S-8 is being filed by Atossa Therapeutics, Inc., a Delaware corporation (the “Company” or the “Registrant”), to register an additional 12,000,000 shares of its common stock, par value $0.18 per share (the “Common Stock”) issuable to eligible individuals under the Atossa Therapeutics, Inc. 2020 Stock Incentive Plan, as amended (the “2020 Plan”).

    The information contained in the Registrant’s Registration Statement on Form S-8 filed with the Securities Exchange Commission (the “Commission”) on March 31, 2021 (Registration No. 333-254905), together with all exhibits filed therewith or incorporated therein by reference, are hereby incorporated by reference pursuant to General Instruction E on Form S-8, and the shares of Common Stock registered hereunder are in addition to the shares of Common Stock registered on such registration statement with respect to the 2020 Plan.

    PART II
    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 8. Exhibits.

    EXHIBIT INDEX

    Incorporated by Reference Herein

    Exhibit No.

    Description

    Form

    Date

    4.1

    Amended and Restated Certificate of Incorporation of Atossa Therapeutics, Inc.

    Registration Statement on Form S-1/A, as Exhibit 3.2

    June 11, 2012

    4.2

    Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Atossa Therapeutics, Inc.

    Current Report on Form 8-K, as Exhibit 4.1

    August 26, 2016

    4.3

    Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Atossa Therapeutics, Inc.

    Current Report on Form 8-K, as Exhibit 4.1

    April 23, 2018

    4.4

    Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Atossa Therapeutics, Inc.

    Current Report on Form 8-K, as Exhibit 3.1

    January 7, 2020

    4.5

    Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Atossa Therapeutics, Inc.

    Current Report on Form 8-K, as Exhibit 3.1

    July 2, 2024

    4.6

    Amended and Restated Bylaws of Atossa Therapeutics, Inc.

    Current Report on Form 8-K, as Exhibit 3.2

    April 26, 2023

    5.1*

    Opinion of Gibson, Dunn & Crutcher LLP

    Filed herewith

    23.1*

    Consent of Gibson, Dunn & Crutcher LLP

    Included in Exhibit 5.1

    23.2*

    Consent of Ernst & Young LLP

    Filed herewith

    24.1*

    Power of Attorney

     

    99.1

    Atossa Therapeutics, Inc. 2020 Stock Incentive Plan, as amended June 27, 2024

    Current Report on Form 8-K, as Exhibit 10.1

     

    July 2, 2024

    107*

    Filing Fee Table

    Filed herewith

    *Filed herewith.

    SIGNATURES


    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Seattle, State of Washington, on this March 26, 2025.

    Atossa Therapeutics, Inc.

    By:

    /s/ Heather Rees

    Name:

    Heather Rees

    Title:

    Chief Financial Officer and Secretary

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Steven C. Quay, M.D., Ph.D. and Heather Rees, and each of them, his true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments, including post-effective amendments, to this Registration Statement, and any registration statement relating to the offering covered by this Registration Statement and filed pursuant to Rule 462(b) under the Securities Act of 1933, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that each of said attorneys-in-fact and agents or their substitute or substitutes may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

    Signature

    Office(s)

    Date

    /s/ Steven C. Quay

    Chairman, President and Chief Executive Officer

    March 26, 2025

    Steven C. Quay, M.D., Ph.D.

    (Principal Executive Officer)

    /s/ Heather Rees

    Chief Financial Officer and Secretary

    March 26, 2025

    Heather Rees

     

    /s/ Richard I. Steinhart

    Director

    March 26, 2025

    Richard I. Steinhart

    /s/ Shu-Chih Chen

    Director

    March 26, 2025

    Shu-Chih Chen, Ph.D.

    /s/ Jonathan Finn

    Director

    March 26, 2025

    Jonathan Finn

    /s/ Stephen J. Galli

    Director

    March 26, 2025

    Stephen J. Galli, M.D.

    /s/ H. Lawrence Remmel

    Director

    March 26, 2025

    H. Lawrence Remmel

    /s/ Tessa Cigler

    Director

    March 26, 2025

    Tessa Cigler, M.D., M.P.H.



    Get the next $ATOS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATOS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ATOS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CEO Quay Steven C bought $9,887 worth of shares (11,239 units at $0.88), increasing direct ownership by 423% to 13,898 units (SEC Form 4)

    4 - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)

    5/22/25 6:27:25 PM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Remmel H. Lawrence bought $7,000 worth of shares (10,000 units at $0.70), increasing direct ownership by 3,891% to 10,257 units (SEC Form 4)

    4 - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)

    3/28/25 4:00:03 PM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Finn Jonathan bought $44,250 worth of shares (25,000 units at $1.77) (SEC Form 4)

    4 - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)

    4/11/24 4:05:09 PM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATOS
    Leadership Updates

    Live Leadership Updates

    View All

    Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

    Announced positive topline results from KARISMA-Endoxifen Phase 2 study which demonstrated that low doses of (Z)-endoxifen significantly reduced mammographic breast density (MBD), addressing a key breast cancer risk factorReleased a preliminary analysis from I-SPY 2 Endocrine Optimization Pilot (EOP) Phase 2 trial of (Z)-endoxifen which met the primary endpoint with 95 percent (19/20 patients) receiving > 75 percent of planned treatmentAnnounced the dosing of the first patient in a clinical trial conducted in partnership with Quantum Leap Healthcare Collaborativeä evaluating Atossa's proprietary (Z)-endoxifen in combination with abemaciclib (VERZENIO)Received a new patent (U.S. Patent No. 12

    11/12/24 8:30:00 AM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Atossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product Development

    SEATTLE, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), today announced the appointment of Claudia Lopez, DVM, MSc, as its new Vice President, Clinical Product Development. Dr. Lopez brings more than two decades of clinical development and strategic expertise to Atossa, including leadership roles in global clinical programs across immunology, oncology, and metabolic disease. Atossa Therapeutics is a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer. Dr. Lopez most recently served as Vice President of Clinical Development at Landos Biopharma, where she oversaw global clinical strategies, trial

    11/5/24 8:30:00 AM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Atossa Therapeutics Announces the Appointment of Michael Parks as Vice President, Investor and Public Relations

    SEATTLE, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) today announced the appointment of Michael Parks as Vice President of Investor and Public Relations. Mr. Parks brings nearly 30 years of investor relations and corporate communications experience working globally within the biopharmaceutical and healthcare industries. He will oversee corporate, executive, and digital communications, investor relations, thought leadership, and branding for the Company. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer. "We are excited to welcome Michael t

    8/20/24 8:30:00 AM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATOS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Atossa Therapeutics Selects PSI as Contract Research Organization for Pivotal Dose-Ranging Study of (Z)-Endoxifen in Metastatic Breast Cancer

    Monotherapy Phase 2 study designed with FDA input; IND expected in Q4 2025 Topline results anticipated in 2026  Positions Atossa for transition into registrational Phase 3 development SEATTLE, Aug. 20, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, announced today it has selected PSI, a leading global contract research organization (CRO), to operationalize and manage its planned (Z)-endoxifen monotherapy dose-ranging study in women with metastatic breast cancer (mBC). The study was designed following guidance from the U.S. Food and Drug Administration (FDA)

    8/20/25 8:30:00 AM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Atossa Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Corporate Update

    FDA Provides Positive Feedback, Clears Path for Atossa to File IND for (Z)-Endoxifen in Metastatic Breast Cancer; FDA Indicates No Additional Toxicity Studies Required Strong I-SPY2 Results Reinforce Efficacy of Atossa's Monotherapy at 3-weeks SEATTLE, Aug. 12, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced its financial results for the second quarter ended June 30, 2025 and provided an update on recent company developments. "Atos

    8/12/25 8:30:00 AM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Atossa Therapeutics Announces Positive FDA Feedback, Advances Toward IND for (Z)-Endoxifen Clinical Program in ER+/HER2- Metastatic Breast Cancer

    SEATTLE, July 29, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing innovative medicines in oncology, today announced positive written feedback from the U.S. Food and Drug Administration (FDA) regarding the company's proposed dose optimization trial of (Z)-endoxifen for the treatment of estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer. With the FDA's feedback, Atossa is energized and moving quickly to advance (Z)-endoxifen in metastatic breast c

    7/29/25 7:45:00 AM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATOS
    SEC Filings

    View All

    Atossa Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - ATOSSA THERAPEUTICS, INC. (0001488039) (Filer)

    8/21/25 4:05:28 PM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Atossa Therapeutics Inc.

    10-Q - ATOSSA THERAPEUTICS, INC. (0001488039) (Filer)

    8/12/25 8:45:46 AM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Atossa Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - ATOSSA THERAPEUTICS, INC. (0001488039) (Filer)

    8/12/25 8:40:29 AM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATOS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CEO Quay Steven C bought $9,887 worth of shares (11,239 units at $0.88), increasing direct ownership by 423% to 13,898 units (SEC Form 4)

    4 - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)

    5/22/25 6:27:25 PM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Finn Jonathan

    4 - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)

    5/16/25 4:05:23 PM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Steinhart Richard I

    4 - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)

    5/16/25 4:05:09 PM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATOS
    Financials

    Live finance-specific insights

    View All

    Atossa Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Corporate Update

    FDA Provides Positive Feedback, Clears Path for Atossa to File IND for (Z)-Endoxifen in Metastatic Breast Cancer; FDA Indicates No Additional Toxicity Studies Required Strong I-SPY2 Results Reinforce Efficacy of Atossa's Monotherapy at 3-weeks SEATTLE, Aug. 12, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced its financial results for the second quarter ended June 30, 2025 and provided an update on recent company developments. "Atos

    8/12/25 8:30:00 AM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Atossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate Update

    Announced strategic plan to advance (Z)-endoxifen for metastatic breast cancer indication  Enhanced (Z)-endoxifen intellectual property portfolio with three new U.S. patents, expanding IP portfolio to more than 200 patent claims related to (Z)-endoxifen Ended first quarter 2025 with $65.1 million in cash and cash equivalents and no debt SEATTLE, May 13, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced its financial results for the first quarter ended March 31, 2025 and provided an update on recent company developments.

    5/13/25 8:00:00 AM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update

    Ended 2024 with $71.1 million of cash and cash equivalents and no debt Conference Call and Webcast Scheduled for Tuesday, March 25, 2025, at 8:30 a.m. Eastern Time SEATTLE, March 25, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced its financial results for the full year ended December 31, 2024 and provided an update on recent company developments. Fourth Quarter and Early 2025 Highlights Strategic Decision to Pursue Metastatic Breast Cancer Indication: Atossa plans to advance its lead program, (Z)-endoxifen, to target metastatic bre

    3/25/25 8:00:00 AM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATOS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Atossa Therapeutics Inc.

    SC 13G/A - ATOSSA THERAPEUTICS, INC. (0001488039) (Subject)

    11/12/24 1:32:30 PM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Atossa Therapeutics Inc.

    SC 13G/A - ATOSSA THERAPEUTICS, INC. (0001488039) (Subject)

    11/4/24 11:27:58 AM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Atossa Therapeutics Inc. (Amendment)

    SC 13G/A - ATOSSA THERAPEUTICS, INC. (0001488039) (Subject)

    2/9/23 11:07:47 AM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care